Arcus Biosciences, INC. (RCUS) — SEC Filings

Overview

Arcus Biosciences, INC. (RCUS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 20, 2026: Arcus Biosciences, Inc. filed an 8-K on April 20, 2026, reporting other events. The filing does not contain specific financial figures or material events beyond the reporting of an event.

Sentiment Summary

Across 38 filings, the sentiment breakdown is: 6 bullish, 1 bearish, 28 neutral, 3 mixed. The dominant filing sentiment for Arcus Biosciences, INC. is neutral.

Filing Type Overview

Arcus Biosciences, INC. (RCUS) has filed 18 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13D/A, 6 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (38)

• Arcus Biosciences Files 8-K — 8-K · Apr 20, 2026 Risk: low
  Arcus Biosciences, Inc. filed an 8-K on April 20, 2026, reporting other events. The filing does not contain specific financial figures or material events beyond
• Arcus Biosciences Enters Material Definitive Agreement — 8-K · Dec 18, 2025 Risk: medium
  On December 18, 2025, Arcus Biosciences, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, headquartered i
• 8-K Filing — 8-K · Dec 12, 2025
• 8-K Filing — 8-K · Nov 3, 2025
• Arcus Biosciences' Losses Widen Amid Increased R&D Spend — 10-Q · Oct 28, 2025 Risk: high
  Arcus Biosciences, Inc. (RCUS) reported a net loss of $135 million for the three months ended September 30, 2025, a significant increase from the $92 million ne
• Gilead to Acquire Arcus Biosciences for $12.8B — 8-K · Oct 14, 2025 Risk: medium
  Arcus Biosciences, Inc. announced on October 12, 2025, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. The transaction i
• Arcus Biosciences Files 8-K — 8-K · Oct 6, 2025 Risk: low
  Arcus Biosciences, Inc. filed an 8-K on October 6, 2025, reporting an event under 'Other Events'. The filing does not contain specific details about the event i
• Arcus Biosciences Revenue Soars 105% on Collaboration Boost — 10-Q · Aug 6, 2025 Risk: medium
  Arcus Biosciences reported a significant increase in total revenue for the three and six months ended June 30, 2025, primarily driven by collaboration agreement
• Arcus Biosciences Files 8-K with Shareholder Vote and Financials — 8-K · Jun 12, 2025 Risk: low
  Arcus Biosciences, Inc. filed an 8-K on June 12, 2025, reporting on matters submitted to a vote of security holders and other events. The filing includes financ
• Gilead to Acquire Arcus Biosciences for $12.8B — 8-K · Jun 2, 2025 Risk: medium
  Arcus Biosciences, Inc. announced on June 1, 2025, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for approximately $12
• Arcus Biosciences Q1 2025 Update — 10-Q · May 6, 2025 Risk: medium
  Arcus Biosciences, Inc. reported its first quarter 2025 results, ending March 31, 2025. The company's revenue streams include License and Development Services R
• Arcus Biosciences Files 2025 Proxy Statement on Executive Pay — DEF 14A · Apr 22, 2025 Risk: low
  Arcus Biosciences, Inc. filed its DEF 14A on April 22, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes
• Arcus Biosciences Files 2024 10-K — 10-K · Feb 25, 2025 Risk: medium
  Arcus Biosciences, Inc. filed its 2024 10-K on February 25, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on pharmaceutical
• Arcus Biosciences Files 8-K: Other Events & Exhibits — 8-K · Feb 19, 2025 Risk: low
  Arcus Biosciences, Inc. filed an 8-K on February 19, 2025, reporting other events and financial statements/exhibits. The filing date is February 19, 2025, with
• Arcus Biosciences Files 8-K — 8-K · Feb 18, 2025 Risk: low
  Arcus Biosciences, Inc. filed an 8-K on February 18, 2025, reporting on results of operations and other events as of February 15, 2025. The filing does not cont
• Arcus Biosciences CEO Departs, New CEO Appointed — 8-K · Feb 6, 2025 Risk: medium
  Arcus Biosciences, Inc. announced on February 6, 2025, the departure of Dr. Terry Rosen from his role as Chief Executive Officer and a member of the Board of Di
• Arcus Biosciences Elects New Directors, Adjusts Executive Pay — 8-K · Jan 21, 2025 Risk: medium
  Arcus Biosciences, Inc. announced on January 16, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company elec
• Rosen Amends Arcus Biosciences Stake Filing — SC 13D/A · Dec 17, 2024 Risk: medium
  Terry J. Rosen, through an amendment filed on December 17, 2024, has updated his Schedule 13D filing for Arcus Biosciences, Inc. The filing indicates a change i
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G/A Filing — SC 13G/A · Nov 8, 2024
• Arcus Biosciences Q3 2024 10-Q Filed — 10-Q · Nov 6, 2024 Risk: medium
  Arcus Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported License and Development Services Revenue for the third qua
• Gilead to Acquire Arcus Biosciences for $12.8B — 8-K · Oct 24, 2024 Risk: medium
  Arcus Biosciences, Inc. announced on October 24, 2024, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for approximately
• SC 13G/A Filing — SC 13G/A · Oct 23, 2024
• SC 13G/A Filing — SC 13G/A · Oct 17, 2024
• Arcus Biosciences Enters New Credit Agreement — 8-K · Aug 27, 2024 Risk: medium
  On August 27, 2024, Arcus Biosciences, Inc. entered into a material definitive agreement, specifically a credit agreement with certain lenders. This agreement c
• Arcus Biosciences Q2 Revenue Surges on Licensing Deals — 10-Q · Aug 8, 2024 Risk: medium
  Arcus Biosciences, Inc. reported its Q2 2024 results, with total revenue for the three months ended June 30, 2024, reaching $40.8 million, a significant increas
• Arcus Biosciences Files 8-K — 8-K · Jun 6, 2024 Risk: low
  Arcus Biosciences, Inc. filed an 8-K on June 6, 2024, to report on the submission of matters to a vote of security holders, other events, and financial statemen
• Gilead to Acquire Arcus Biosciences for $12.8B — 8-K · Jun 3, 2024 Risk: medium
  Arcus Biosciences, Inc. announced on June 2, 2024, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for approximately $12
• Gilead to Acquire Arcus Biosciences for $12.8 Billion — 8-K · May 23, 2024 Risk: medium
  Arcus Biosciences, Inc. announced on May 23, 2024, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for approximately $12
• Arcus Biosciences, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk: medium
  Arcus Biosciences, Inc. (RCUS) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Arcus Biosciences reported License and Development Services Revenue
• Arcus Biosciences, Inc. Files Definitive Proxy Statement — DEF 14A · Apr 23, 2024 Risk: low
  Arcus Biosciences, Inc. (RCUS) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Arcus Biosciences, Inc. filed a Definitive Proxy Statement (DEF
• Arcus Biosciences, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 21, 2024 Risk: medium
  Arcus Biosciences, Inc. (RCUS) filed a Annual Report (10-K) with the SEC on February 21, 2024. Arcus Biosciences, Inc. filed its 2023 Form 10-K on February 21,
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• FMR LLC Discloses 6.317% Passive Stake in Arcus Biosciences — SC 13G · Feb 9, 2024 Risk: low
  FMR LLC, a major investment management firm, and its Chair and CEO, Abigail P. Johnson, have reported a significant passive stake of 6.317% in Arcus Biosciences
• Gilead Amends Arcus Biosciences Stake, Signals Ownership Change — SC 13D/A · Jan 31, 2024
  Gilead Sciences, Inc. filed an amendment to its Schedule 13D, indicating a change in its beneficial ownership of Arcus Biosciences, Inc. common stock as of Janu
• Arcus Biosciences Reports Material Agreement, Equity Sales, Officer Comp Changes — 8-K · Jan 30, 2024
  Arcus Biosciences, Inc. filed an 8-K on January 30, 2024, reporting events from January 29, 2024, including entering into a material definitive agreement, unreg
• State Street Corp. Discloses Passive Stake in Arcus Biosciences — SC 13G · Jan 24, 2024
  State Street Corporation, a major financial institution, has filed an initial SC 13G indicating its ownership of Arcus Biosciences, Inc. common stock as of Dece
• BlackRock Trims Arcus Biosciences Stake to 9.0% — SC 13G/A · Jan 23, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 23, 2024, disclosing its ownership in Arcus Biosciences, Inc. as of December 31, 2023. This filing indicates

Related Companies

GILD

Frequently Asked Questions